Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study
Abstract The optimization of bridging regimen before chimeric antigen receptor (CAR)-T cell therapy in diffuse large B-cell lymphoma (DLBCL) may impact CAR-T efficacy and outcome. This retrospective study evaluates CAR-T outcome after bridging with radiotherapy (RT) and other bridging strategies. Among 148 patients with relapsed/refractory DLBCL who underwent leukapheresis for CAR-T manufacturing, 31 received RT-bridging, 84 chemotherapy (CT), 33 no-bridging or steroid-only. CAR-T cell were infused in 96.8% of RT-group. 89.2% of CT-group and 78.8% of no-bridge group (p = 0.079). Response to bridging was generally poor, but patients receiving RT had a significant reduction in LDH levels between pre- and post-bridging (p = 0.05). The one-year PFS was 51.2% in the RT group, 28.2% in the CT group, and 47.6% in the no-bridge group (p = 0.044); 1-year OS was 86.7% in the RT group, 52.7% in the CT group and 69% in the no-bridge group (p = 0.025). We observed a higher incidence of ICANS in patients who received CT than in others (20.0% CT group, 3.3% RT group, 7.7% no-bridge group; p = 0.05). In conclusion, RT-bridging is associated with lower drop-out rate and CAR-T toxicity, and it might be preferred to other bridging strategies for patients with localized disease or for those with one prevalent symptomatic site..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 20. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mannina, Daniele [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3573162/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA041606590 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA041606590 | ||
| 003 | DE-627 | ||
| 005 | 20231205143642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231121s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3573162/v1 |2 doi | |
| 035 | |a (DE-627)XRA041606590 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3573162/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mannina, Daniele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The optimization of bridging regimen before chimeric antigen receptor (CAR)-T cell therapy in diffuse large B-cell lymphoma (DLBCL) may impact CAR-T efficacy and outcome. This retrospective study evaluates CAR-T outcome after bridging with radiotherapy (RT) and other bridging strategies. Among 148 patients with relapsed/refractory DLBCL who underwent leukapheresis for CAR-T manufacturing, 31 received RT-bridging, 84 chemotherapy (CT), 33 no-bridging or steroid-only. CAR-T cell were infused in 96.8% of RT-group. 89.2% of CT-group and 78.8% of no-bridge group (p = 0.079). Response to bridging was generally poor, but patients receiving RT had a significant reduction in LDH levels between pre- and post-bridging (p = 0.05). The one-year PFS was 51.2% in the RT group, 28.2% in the CT group, and 47.6% in the no-bridge group (p = 0.044); 1-year OS was 86.7% in the RT group, 52.7% in the CT group and 69% in the no-bridge group (p = 0.025). We observed a higher incidence of ICANS in patients who received CT than in others (20.0% CT group, 3.3% RT group, 7.7% no-bridge group; p = 0.05). In conclusion, RT-bridging is associated with lower drop-out rate and CAR-T toxicity, and it might be preferred to other bridging strategies for patients with localized disease or for those with one prevalent symptomatic site. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Bramanti, Stefania |0 (orcid)0000-0002-4117-7991 |4 aut | |
| 700 | 1 | |a Chiappella, Annalisa |0 (orcid)0000-0002-2977-0098 |4 aut | |
| 700 | 1 | |a Casadei, Beatrice |4 aut | |
| 700 | 1 | |a De Philippis, Chiara |0 (orcid)0000-0002-7738-997X |4 aut | |
| 700 | 1 | |a Giordano, Laura |4 aut | |
| 700 | 1 | |a Navarria, Pierina |4 aut | |
| 700 | 1 | |a Mancosu, Pietro |4 aut | |
| 700 | 1 | |a Taurino, Daniela |4 aut | |
| 700 | 1 | |a Scorsetti, Marta |4 aut | |
| 700 | 1 | |a Carlo-Stella, Carmelo |0 (orcid)0000-0003-3144-0124 |4 aut | |
| 700 | 1 | |a Zinzani, Pier Luigi |0 (orcid)0000-0002-2112-2651 |4 aut | |
| 700 | 1 | |a Santoro, Armando |4 aut | |
| 700 | 1 | |a Corradini, Paolo |0 (orcid)0000-0002-9186-1353 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 20. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:20 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3573162/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 20 |c 11 | ||